 |
14 Diseases |  |
33 Trials |
|
33 Trials |  |
2608 News |  |
| «12...20212223242526272829303132 |
- |||| teriflunomide / Generic mfg.
Trial completion, Patient reported outcomes: TERI-PRO: Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients (clinicaltrials.gov) - Dec 4, 2015
P4, N=1001, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed
- teriflunomide / Generic mfg.
New P3 trial: TERICIS: A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period (clinicaltrials.gov) - Oct 27, 2015
P3, N=11, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de Nice
- Tysabri (natalizumab) / Biogen, Royalty
Trial primary completion date: MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV (clinicaltrials.gov) - Sep 24, 2015
P4, N=70, Recruiting, Sponsor: Multiple Sclerosis Center of Northeastern New York
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2016
- ||||||| teriflunomide / Generic mfg.
Trial completion: TOWER: An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis (clinicaltrials.gov) - Sep 9, 2015
P3, N=1169, Completed, Sponsor: Sanofi
Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed
- teriflunomide / Generic mfg., colestipol / Generic mfg.
Trial primary completion date: TERCOL: Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride (clinicaltrials.gov) - Aug 21, 2015
P1, N=30, Recruiting, Sponsor: Derrick Scott Robertson
Active, not recruiting --> Completed Trial primary completion date: Aug 2015 --> Dec 2015
- | teriflunomide / Generic mfg.
New P4 trial: Teriflunomide Observational Effectiveness Study (clinicaltrials.gov) - Jul 8, 2015
P4, N=300, Not yet recruiting, Sponsor: Centre hospitalier de l'Universit
- ||||||| Rebif (human IFN-?-1a) / EMD Serono
Trial completion: TENERE: A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis (clinicaltrials.gov) - Jun 26, 2015
P3, N=324, Completed, Sponsor: Sanofi
Trial primary completion date: Aug 2015 --> Dec 2015 Active, not recruiting --> Completed
- farudodstat (ASLAN003) / Almirall, ASLAN Pharma
Trial completion, Enrollment change: A Phase 1, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects (clinicaltrials.gov) - Jun 23, 2015
P1, N=7, Completed, Sponsor: Aslan Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed | N=16 --> 7
- |||||| Ponvory (ponesimod) / Juvise Pharma, Vanda
Enrollment open, Head-to-Head: OPTIMUM: Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis (clinicaltrials.gov) - May 24, 2015
P3, N=1100, Recruiting, Sponsor: Actelion
Recruiting --> Completed | N=16 --> 7 Not yet recruiting --> Recruiting
- |||||||||| Ponvory (ponesimod) / Juvise Pharma, Vanda
New P3 trial, Head-to-Head: OPTIMUM: Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis (clinicaltrials.gov) - Apr 25, 2015
P3, N=1100, Not yet recruiting, Sponsor: Actelion
- |||| teriflunomide / Generic mfg.
Trial completion: Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses (clinicaltrials.gov) - Mar 25, 2015
P2, N=147, Completed, Sponsor: Sanofi
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| teriflunomide / Generic mfg.
Enrollment closed, Patient reported outcomes: TERI-PRO: Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients (clinicaltrials.gov) - Feb 9, 2015
P4, N=1000, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- farudodstat (ASLAN003) / Almirall, ASLAN Pharma
New P1 trial: A Phase 1, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects (clinicaltrials.gov) - Jan 22, 2015
P1, N=16, Recruiting, Sponsor: Aslan Pharmaceuticals
- teriflunomide / Generic mfg., colestipol / Generic mfg.
Enrollment open, Trial initiation date: TERCOL: Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride (clinicaltrials.gov) - Jan 15, 2015
P1, N=30, Recruiting, Sponsor: Derrick Scott Robertson
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Oct 2014 --> Jan 2015
- ||||||| teriflunomide / Generic mfg.
Trial completion, Immune cell: Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis (clinicaltrials.gov) - Dec 13, 2014
P3, N=70, Completed, Sponsor: Sanofi
Not yet recruiting --> Recruiting | Initiation date: Oct 2014 --> Jan 2015 Active, not recruiting --> Completed
- | teriflunomide / Generic mfg., colestipol / Generic mfg.
New P1 trial: TERCOL: Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride (clinicaltrials.gov) - Oct 15, 2014
P1, N=30, Not yet recruiting, Sponsor: Derrick Scott Robertson
- ||||| teriflunomide / Generic mfg.
Enrollment closed, Immune cell: Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis (clinicaltrials.gov) - Sep 5, 2014
P3, N=68, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | teriflunomide / Generic mfg.
Trial completion: A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers (clinicaltrials.gov) - Aug 21, 2014
P1, N=12, Completed, Sponsor: Sanofi
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||| teriflunomide / Generic mfg.
Enrollment open: TERIKIDS: Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Jul 30, 2014
P3, N=165, Recruiting, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| teriflunomide / Generic mfg.
New P3 trial: TERIKIDS: Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Jul 27, 2014
P3, N=165, Not yet recruiting, Sponsor: Genzyme, a Sanofi Company
- teriflunomide / Generic mfg.
Enrollment closed: A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers (clinicaltrials.gov) - Jul 23, 2014
P1, N=12, Active, not recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- teriflunomide / Generic mfg.
Trial primary completion date: Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months (clinicaltrials.gov) - Jul 10, 2014
P=N/A, N=50, Recruiting, Sponsor: University at Buffalo
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Nov 2014
- teriflunomide / Generic mfg.
Enrollment open: A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers (clinicaltrials.gov) - Jun 2, 2014
P1, N=12, Recruiting, Sponsor: Sanofi
Trial primary completion date: Jun 2014 --> Nov 2014 Not yet recruiting --> Recruiting
- | teriflunomide / Generic mfg.
New P1 trial: A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers (clinicaltrials.gov) - Jan 26, 2014
P1, N=12, Not yet recruiting, Sponsor: Sanofi
- | Tysabri (natalizumab) / Biogen, Royalty
New P4 trial: MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV (clinicaltrials.gov) - Oct 24, 2013
P4, N=70, Recruiting, Sponsor: Multiple Sclerosis Center of Northeastern New York
- |||||| teriflunomide / Generic mfg.
Enrollment open, Immune cell: Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis (clinicaltrials.gov) - Oct 13, 2013
P3, N=68, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | teriflunomide / Generic mfg.
New P4 trial, Patient reported outcomes: Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients (EUDRACT) - Sep 18, 2013
P4, N=1000, Ongoing, Sponsor: Genzyme Corporation
- |||| teriflunomide / Generic mfg.
Enrollment open, Patient reported outcomes: TERI-PRO: Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients (clinicaltrials.gov) - Jul 9, 2013
P4, N=1000, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| teriflunomide / Generic mfg.
New P4 trial, Patient reported outcomes: TERI-PRO: Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients (clinicaltrials.gov) - Jul 8, 2013
P4, N=1000, Recruiting, Sponsor: Sanofi
- teriflunomide / Generic mfg.
Clinical: Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months (clinicaltrials.gov) - Jun 17, 2013
P=N/A, N=50, Recruiting, Sponsor: University at Buffalo
- | teriflunomide / Generic mfg.
Trial termination: TERACLES: Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta (clinicaltrials.gov) - Jun 5, 2013
P3, N=1455, Terminated, Sponsor: Sanofi
Not yet recruiting --> Recruiting Completed --> Terminated; Sponsor decision to prematurely stop the study, not linked to any safety concern.
- |||||||||| teriflunomide / Generic mfg.
New P3 trial, Immune cell: Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis (clinicaltrials.gov) - May 27, 2013
P3, N=68, Recruiting, Sponsor: Sanofi
- ||||| teriflunomide / Generic mfg.
Enrollment change: TOPIC: Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis (clinicaltrials.gov) - Nov 4, 2012
P3, N=618, Active, not recruiting, Sponsor: Sanofi
Completed --> Terminated; Sponsor decision to prematurely stop the study, not linked to any safety concern. N=780 --> 618
- ||||| teriflunomide / Generic mfg.
Enrollment closed: TOPIC: Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis (clinicaltrials.gov) - Nov 4, 2012
P3, N=618, Active, not recruiting, Sponsor: Sanofi
N=780 --> 618 Recruiting --> Active, not recruiting
- |||| Trial completion: TERIVA: Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide (clinicaltrials.gov) - Feb 2, 2012
P2, N=128, Completed, Sponsor: Sanofi
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Enrollment change: Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis (clinicaltrials.gov) - Jan 9, 2012
P2, N=182, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed N=241 --> 182
- ||||| teriflunomide / Generic mfg.
New P2 trial: Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses (clinicaltrials.gov) - Dec 5, 2011
P2, N=179, Completed, Sponsor: Sanofi